This page has only limited features, please log in for full access.
In March 2020, several mass gathering events were related to the Falles festival in Borriana (Spain), resulting in a 536 laboratory-confirmed COVID-19 cases outbreak among participants. This article estimates anti-SARS-CoV-2 antibodies persistence six months after and factors associated with antibody response. A prospective population-based cohort study was carried out by the Public Health Centre of Castellon and the Emergency and Clinical Analysis and Microbiology Services of Hospital de la Plana in Vila-real. In October 2020, a seroepidemiologic study was used to estimate the persistence of anti-SARS-CoV-2 antibodies against nucleocapsid protein (N) by an electrochemiluminescence immunoassay (ECLIA) was implemented. We enrolled 484 (90.2%) of the 536 members of the initial outbreak cohort and detected persistent antibodies in 479 (99%) without reinfection episodes. Five participants had a negative antibody test. Factors associated with a negative result were a lower body mass index (BMI), and less contact with other COVID-19 cases. Among the 469 participants with two ECLIA tests, 96 (20.5%) had an increase of antibodies and 373 (79.5%) a decline. Increased antibodies were associated with older age, higher BMI, more severe illness, and low current smokers. Our results show that after a COVID-19 infection, a high proportion of cases maintain detectable anti-SARS-CoV-2 antibodies.
Salvador Domènech-Montoliu; Joan Puig-Barberà; Maria Pac-Sa; Paula Vidal-Utrillas; Marta Latorre-Poveda; Alba Del Rio-González; Sara Ferrando-Rubert; Gema Ferrer-Abad; Manuel Sánchez-Urbano; Laura Aparisi-Esteve; Gema Badenes-Marques; Belén Cervera-Ferrer; Ursula Clerig-Arnau; Claudia Dols-Bernad; Maria Fontal-Carcel; Lorna Gomez-Lanas; David Jovani-Sales; Maria León-Domingo; Maria Llopico-Vilanova; Mercedes Moros-Blasco; Cristina Notari-Rodríguez; Raquel Ruíz-Puig; Sonia Valls-López; Alberto Arnedo-Pena. Persistence of Anti-SARS-CoV-2 Antibodies Six Months after Infection in an Outbreak with Five Hundred COVID-19 Cases in Borriana (Spain): A Prospective Cohort Study. COVID 2021, 1, 71 -82.
AMA StyleSalvador Domènech-Montoliu, Joan Puig-Barberà, Maria Pac-Sa, Paula Vidal-Utrillas, Marta Latorre-Poveda, Alba Del Rio-González, Sara Ferrando-Rubert, Gema Ferrer-Abad, Manuel Sánchez-Urbano, Laura Aparisi-Esteve, Gema Badenes-Marques, Belén Cervera-Ferrer, Ursula Clerig-Arnau, Claudia Dols-Bernad, Maria Fontal-Carcel, Lorna Gomez-Lanas, David Jovani-Sales, Maria León-Domingo, Maria Llopico-Vilanova, Mercedes Moros-Blasco, Cristina Notari-Rodríguez, Raquel Ruíz-Puig, Sonia Valls-López, Alberto Arnedo-Pena. Persistence of Anti-SARS-CoV-2 Antibodies Six Months after Infection in an Outbreak with Five Hundred COVID-19 Cases in Borriana (Spain): A Prospective Cohort Study. COVID. 2021; 1 (1):71-82.
Chicago/Turabian StyleSalvador Domènech-Montoliu; Joan Puig-Barberà; Maria Pac-Sa; Paula Vidal-Utrillas; Marta Latorre-Poveda; Alba Del Rio-González; Sara Ferrando-Rubert; Gema Ferrer-Abad; Manuel Sánchez-Urbano; Laura Aparisi-Esteve; Gema Badenes-Marques; Belén Cervera-Ferrer; Ursula Clerig-Arnau; Claudia Dols-Bernad; Maria Fontal-Carcel; Lorna Gomez-Lanas; David Jovani-Sales; Maria León-Domingo; Maria Llopico-Vilanova; Mercedes Moros-Blasco; Cristina Notari-Rodríguez; Raquel Ruíz-Puig; Sonia Valls-López; Alberto Arnedo-Pena. 2021. "Persistence of Anti-SARS-CoV-2 Antibodies Six Months after Infection in an Outbreak with Five Hundred COVID-19 Cases in Borriana (Spain): A Prospective Cohort Study." COVID 1, no. 1: 71-82.
In March 2020, several mass gathering events were related to the Falles festival in Borriana (Spain), resulting in a 536 laboratory-confirmed COVID-19 cases outbreak among participants. Our objective was to estimate anti-SARS-CoV-2 antibodies persistence six months after and factors associated with antibody response. A prospective population-based cohort study was carried out by the Public Health Center of Castellon and the Emergency and Clinical Analysis and Microbiology Services of Hospital de la Plana in Vila-real. In October 2020, sero-epidemiologic study to estimate the persistence of anti-SARS-CoV-2 antibodies by a electrochemiluminescence immunoassay (ECLIA) was implemented. We enrolled 484 (90.2%) of the 536 members of the initial outbreak cohort and detected persistent antibodies in 479 (99%) without re-infection episodes. Five participants had a negative antibody test. Factors associated with a negative result were a lower body mass index (BMI), and less contact with other COVID-19 cases. Among the 469 participants with two ECLIA tests, 96 (20.5%) had an increase of antibodies and 373 (79.5%) a decline. Increased antibodies were associated with older age, higher BMI, more severe illness, and low current smokers. After a COVID-19 infection, a high proportion of cases maintained detectable anti-SARS-CoV-2 antibodies.
Salvador Domènech-Montoliu; Joan Puig-Barberà; Maria Rosario Pac-Sa; Paula Vidal-Utrillas; Marta Latorre-Poveda; Alba Del Rio-González; Sara Ferrando-Rubert; Gema Ferrer-Abad; Manuel Sánchez-Urbano; Laura Aparisi-Esteve; Gema Badenes-Marques; Belen Cervera-Ferrer; Ursula Clerig-Arnau; Claudia Dols-Bernad; Maria Fontal-Carcel; Lorna Gomez-Lanas; David Jovani-Sales; Maria Carmen Leòn-Domingo; Maria Dolores Llopico-Vilanova; Mercedes Moros-Blanco; Cristina Notari-Rodríguez; Raquel Ruíz-Puig; Sonia Valls-López; Alberto Arnedo-Pena. Persistence of Anti-SARS-CoV-2 Antibodies Six Months After Infection in an Outbreak With Five Hundred COVID-19 Cases in Borriana (Spain): A Prospective Cohort Study. 2021, 1 .
AMA StyleSalvador Domènech-Montoliu, Joan Puig-Barberà, Maria Rosario Pac-Sa, Paula Vidal-Utrillas, Marta Latorre-Poveda, Alba Del Rio-González, Sara Ferrando-Rubert, Gema Ferrer-Abad, Manuel Sánchez-Urbano, Laura Aparisi-Esteve, Gema Badenes-Marques, Belen Cervera-Ferrer, Ursula Clerig-Arnau, Claudia Dols-Bernad, Maria Fontal-Carcel, Lorna Gomez-Lanas, David Jovani-Sales, Maria Carmen Leòn-Domingo, Maria Dolores Llopico-Vilanova, Mercedes Moros-Blanco, Cristina Notari-Rodríguez, Raquel Ruíz-Puig, Sonia Valls-López, Alberto Arnedo-Pena. Persistence of Anti-SARS-CoV-2 Antibodies Six Months After Infection in an Outbreak With Five Hundred COVID-19 Cases in Borriana (Spain): A Prospective Cohort Study. . 2021; ():1.
Chicago/Turabian StyleSalvador Domènech-Montoliu; Joan Puig-Barberà; Maria Rosario Pac-Sa; Paula Vidal-Utrillas; Marta Latorre-Poveda; Alba Del Rio-González; Sara Ferrando-Rubert; Gema Ferrer-Abad; Manuel Sánchez-Urbano; Laura Aparisi-Esteve; Gema Badenes-Marques; Belen Cervera-Ferrer; Ursula Clerig-Arnau; Claudia Dols-Bernad; Maria Fontal-Carcel; Lorna Gomez-Lanas; David Jovani-Sales; Maria Carmen Leòn-Domingo; Maria Dolores Llopico-Vilanova; Mercedes Moros-Blanco; Cristina Notari-Rodríguez; Raquel Ruíz-Puig; Sonia Valls-López; Alberto Arnedo-Pena. 2021. "Persistence of Anti-SARS-CoV-2 Antibodies Six Months After Infection in an Outbreak With Five Hundred COVID-19 Cases in Borriana (Spain): A Prospective Cohort Study." , no. : 1.
The implementation of strategies to mitigate possible cases of COVID-19 were addressed at the University of Alicante for the safe reopening of the 2020/2021 academic year. To discover the prevalence of immunity against SARS-CoV-2, a study was designed using a rapid immunoassay test (carried out between 6 and 22 July 2020), and in addition a cross-sectional survey was conducted on risk factors, symptoms, predisposition for becoming vaccinated, and sources of information about COVID-19. A random sample, stratified by students, faculty, and administrative staff, was selected. The seroprevalence found was 2.64% (39/1479; 95% CI 1.8–3.4), and the adjusted seroprevalence was 2.89% (95% CI 2.1–3.7). The average age of the students was 23.2 years old, and 47.6 years old for staff. In relation to COVID-19, the following was found: 17.7% pauci-symptomatic, 1.3% symptomatic, 5.5% contact with cases, 4.9% confined, and 0.3% PCR positive. More than 90% complied with preventive measures. The proportion willing to receive the COVID-19 vaccine was 91%. Their sources of information were the Internet (74%) and television (70.1%). They requested that the university offer information (45.1%), training (27%), and provide Personal Protective Equipment (PPE) (26.3%). Lastly, 87.9% would repeat the test. A plan was established that included the follow-up of cases and contacts, random sample testing, training courses, bimodal teaching, a specific website, and the distribution of PPE.
Jose Tuells; Cecilia Egoavil; María Pena Pardo; Ana Montagud; Emilia Montagud; Pablo Caballero; Pedro Zapater; Joan Puig-Barberá; Jose Hurtado-Sanchez. Seroprevalence Study and Cross-Sectional Survey on COVID-19 for a Plan to Reopen the University of Alicante (Spain). International Journal of Environmental Research and Public Health 2021, 18, 1908 .
AMA StyleJose Tuells, Cecilia Egoavil, María Pena Pardo, Ana Montagud, Emilia Montagud, Pablo Caballero, Pedro Zapater, Joan Puig-Barberá, Jose Hurtado-Sanchez. Seroprevalence Study and Cross-Sectional Survey on COVID-19 for a Plan to Reopen the University of Alicante (Spain). International Journal of Environmental Research and Public Health. 2021; 18 (4):1908.
Chicago/Turabian StyleJose Tuells; Cecilia Egoavil; María Pena Pardo; Ana Montagud; Emilia Montagud; Pablo Caballero; Pedro Zapater; Joan Puig-Barberá; Jose Hurtado-Sanchez. 2021. "Seroprevalence Study and Cross-Sectional Survey on COVID-19 for a Plan to Reopen the University of Alicante (Spain)." International Journal of Environmental Research and Public Health 18, no. 4: 1908.
Influenza vaccination is annually recommended for specific populations at risk, such as older adults. We estimated the 2018/2019 influenza vaccine effectiveness (IVE) overall, by influenza subtype, type of vaccine, and by time elapsed since vaccination among subjects 65 years old or over in a multicenter prospective study in the Valencia Hospital Surveillance Network for the Study of Influenza and other Respiratory Viruses (VAHNSI, Spain). Information about potential confounders was obtained from clinical registries and/or by interviewing patients and vaccination details were only ascertained by registries. A test-negative design was performed in order to estimate IVE. As a result, IVE was estimated at 46% (95% confidence interval (CI): (16%, 66%)), 41% (95% CI: (−34%, 74%)), and 45% (95% CI: (7%, 67%)) against overall influenza, A(H1N1)pdm09 and A(H3N2), respectively. An intra-seasonal not relevant waning effect was detected. The IVE for the adjuvanted vaccine in ≥75 years old was 45% (2%, 69%) and for the non-adjuvanted vaccine in 65–74 years old was 59% (−16%, 86%). Thus, our data revealed moderate vaccine effectiveness against influenza A(H3N2) and not significant against A(H1N1)pdm09. Significant protection was conferred by the adjuvanted vaccine to patients ≥75 years old. Moreover, an intra-seasonal not relevant waning effect was detected, and a not significant IVE decreasing trend was observed over time.
Ainara Mira-Iglesias; F. López-Labrador; Javier García-Rubio; Beatriz Mengual-Chuliá; Miguel Tortajada-Girbés; Joan Mollar-Maseres; Mario Carballido-Fernández; Germán Schwarz-Chavarri; Joan Puig-Barberà; Javier Díez-Domingo. Influenza Vaccine Effectiveness and Waning Effect in Hospitalized Older Adults. Valencia Region, Spain, 2018/2019 Season. International Journal of Environmental Research and Public Health 2021, 18, 1129 .
AMA StyleAinara Mira-Iglesias, F. López-Labrador, Javier García-Rubio, Beatriz Mengual-Chuliá, Miguel Tortajada-Girbés, Joan Mollar-Maseres, Mario Carballido-Fernández, Germán Schwarz-Chavarri, Joan Puig-Barberà, Javier Díez-Domingo. Influenza Vaccine Effectiveness and Waning Effect in Hospitalized Older Adults. Valencia Region, Spain, 2018/2019 Season. International Journal of Environmental Research and Public Health. 2021; 18 (3):1129.
Chicago/Turabian StyleAinara Mira-Iglesias; F. López-Labrador; Javier García-Rubio; Beatriz Mengual-Chuliá; Miguel Tortajada-Girbés; Joan Mollar-Maseres; Mario Carballido-Fernández; Germán Schwarz-Chavarri; Joan Puig-Barberà; Javier Díez-Domingo. 2021. "Influenza Vaccine Effectiveness and Waning Effect in Hospitalized Older Adults. Valencia Region, Spain, 2018/2019 Season." International Journal of Environmental Research and Public Health 18, no. 3: 1129.
Mortality due to cardiovascular disease (CVD), including cerebrovascular disease (CED) and ischaemic heart disease (IHD), was considerably different in eight municipalities of the province of Castellón, Community of Valencia (Spain) during the period of 1991–2011. In addition, these villages showed differences in agricultural practices and production. Since high vegetable consumption has been linked to decreased all-cause, CVD, and CED mortalities, we hypothesized that the diversity in vegetable and artichoke production, used as proxies for their consumption, could be associated with the diversity of mortality rates. In order to test our hypothesis, we estimated the smoothed standardized mortality ratios (SMRs) of CVD, CED, and IHD mortalities and a directed, age-adjusted mortality rate (AMR). We used a multilevel linear regression analysis to account for the ecological nature of our study. After adjustment, the CVD and CED SMRs were inversely associated with vegetable and artichoke production, with a reduction in SMRs for CVD: −0.19 (95% Confidence Interval [CI] −0.31 to −0.07) and −0.42 (95% CI −0.70 to −0.15) per hectare/103 inhabitants, respectively. The SMRs for CED also decreased: −0.68 (95% CI −1.61 to −0.19) and −1.47 (95% CI −2.57 to −0.36) per hectare/103 inhabitants, respectively. The SMRs for IHD were not associated with vegetal and artichoke production. When the directed AMR was used, CED mortality was consistent with the previous results, whereas the CVD mortality association was lost. Our results indicate that vegetable and artichoke production may act as protective factors of CED and CVD mortalities.
Alberto Arnedo-Pena; Joan Puig-Barberà; Juan Bellido-Blasco; MªAngeles Romeu-Garcia; Mª Rosario Pac-Sa; Francisco Guillen-Grima. Production of Vegetables and Artichokes Is Associated with Lower Cardiovascular Mortality: An Ecological Study. International Journal of Environmental Research and Public Health 2020, 17, 6583 .
AMA StyleAlberto Arnedo-Pena, Joan Puig-Barberà, Juan Bellido-Blasco, MªAngeles Romeu-Garcia, Mª Rosario Pac-Sa, Francisco Guillen-Grima. Production of Vegetables and Artichokes Is Associated with Lower Cardiovascular Mortality: An Ecological Study. International Journal of Environmental Research and Public Health. 2020; 17 (18):6583.
Chicago/Turabian StyleAlberto Arnedo-Pena; Joan Puig-Barberà; Juan Bellido-Blasco; MªAngeles Romeu-Garcia; Mª Rosario Pac-Sa; Francisco Guillen-Grima. 2020. "Production of Vegetables and Artichokes Is Associated with Lower Cardiovascular Mortality: An Ecological Study." International Journal of Environmental Research and Public Health 17, no. 18: 6583.
There are few atopic dermatitis (AD) incidence cohort studies in young adults, the etiology of this disease remains obscure, and AD risk factors in adults are not well understood. The objective of this study was to estimate AD ten-year incidence and prevalence in a cohort of adolescent aged 14–16 at inception in Castellon province in Valencia Region, Spain and describe related risk factors. From 2002 to 2012, a population-based prospective cohort study was carried out. Questionnaires from the International Study of Asthma and Allergies in Childhood (ISAAC) were used with an additional questionnaire for related factors completed by participants and their parents, respectively, in 2002. In 2012 the same questionnaires were completed by the participants’ through a telephone interview, and incidence and prevalence of AD were estimated. Directed acyclic graphs, Poisson regression and inverse probability weighted regression adjustment were used. The participation rate was 79.5% (1435/1805) with AD lifetime prevalence of 34.9% and AD incidence of 13.5 per 1000 person years. Females presented higher prevalence and incidence than males. After adjustment significant risk factors were being female, history of asthma or allergic rhinitis, family history of AD, history of respiratory infections, history of bronchitis, history of pneumonia, history of sinusitis, and birthplace outside Castellon province. The highest AD population attributable risks were female, 30.3%, and history of respiratory infections 15.3%. Differences with AD childhood risk factors were found. AD incidence in our cohort was high and several risks factors were related to AD.
A. Arnedo-Pena; J. Puig-Barberà; A. Artero-Civera; M.A. Romeu-Garcia; N. Meseguer-Ferrer; C. Fenollosa-Amposta; A. Vizcaino-Batllés; E. Silvestre-Silvester; M.R. Pac-Sa; L. Segura-Navas; M.A. Dubón; J. Fabregat-Puerto; J.B. Bellido-Blasco. Atopic dermatitis incidence and risk factors in young adults in Castellon (Spain): A prospective cohort study. Allergologia et Immunopathologia 2020, 48, 694 -700.
AMA StyleA. Arnedo-Pena, J. Puig-Barberà, A. Artero-Civera, M.A. Romeu-Garcia, N. Meseguer-Ferrer, C. Fenollosa-Amposta, A. Vizcaino-Batllés, E. Silvestre-Silvester, M.R. Pac-Sa, L. Segura-Navas, M.A. Dubón, J. Fabregat-Puerto, J.B. Bellido-Blasco. Atopic dermatitis incidence and risk factors in young adults in Castellon (Spain): A prospective cohort study. Allergologia et Immunopathologia. 2020; 48 (6):694-700.
Chicago/Turabian StyleA. Arnedo-Pena; J. Puig-Barberà; A. Artero-Civera; M.A. Romeu-Garcia; N. Meseguer-Ferrer; C. Fenollosa-Amposta; A. Vizcaino-Batllés; E. Silvestre-Silvester; M.R. Pac-Sa; L. Segura-Navas; M.A. Dubón; J. Fabregat-Puerto; J.B. Bellido-Blasco. 2020. "Atopic dermatitis incidence and risk factors in young adults in Castellon (Spain): A prospective cohort study." Allergologia et Immunopathologia 48, no. 6: 694-700.
Introduction Influenza immunisation is recommended for elderly people each season. The influenza vaccine effectiveness (IVE) varies annually due to influenza viruses evolving and the vaccine composition. Aim To estimate, in inpatients ≥ 60 years old, the 2017/18 trivalent IVE, overall, by vaccine type and by strain. The impact of vaccination in any of the two previous seasons (2016/17 and 2015/16) on current (2017/18) IVE was also explored. Methods This was a multicentre prospective observational study within the Valencia Hospital Surveillance Network for the Study of Influenza and Respiratory Viruses Disease (VAHNSI, Spain). The test-negative design was applied taking laboratory-confirmed influenza as outcome and vaccination status as main exposure. Information about potential confounders was obtained from clinical registries and/or by interviewing patients; vaccine information was only ascertained by registries. Results Overall, 2017/18 IVE was 9.9% (95% CI: −15.5 to 29.6%), and specifically, 48.3% (95% CI: 13.5% to 69.1%), −29.9% (95% CI: −79.1% to 5.8%) and 25.7% (95% CI: −8.8% to 49.3%) against A(H1N1)pdm09, A(H3N2) and B/Yamagata lineage, respectively. For the adjuvanted and non-adjuvanted vaccines, overall IVE was 10.0% (95% CI: −24.4% to 34.9%) and 7.8% (95% CI: −23.1% to 31.0%) respectively. Prior vaccination significantly protected against influenza B/Yamagata lineage (IVE: 50.2%; 95% CI: 2.3% to 74.6%) in patients not vaccinated in the current season. For those repeatedly vaccinated against influenza A(H1N1)pdm09, IVE was 46.4% (95% CI: 6.8% to 69.2%). Conclusion Our data revealed low vaccine effectiveness against influenza in hospitalised patients ≥60 years old in 2017/18. Prior vaccination protected against influenza A(H1N1)pdm09 and B/Yamagata-lineage.
Ainara Mira-Iglesias; F Xavier López-Labrador; Víctor Baselga-Moreno; Miguel Tortajada-Girbés; Juan Mollar-Maseres; Mario Carballido-Fernández; Germán Schwarz-Chavarri; Joan Puig-Barberà; Javier Díez-Domingo; on behalf of the Valencia Hospital Network for the Study of Influenza and Respiratory Viruses Disease. Influenza vaccine effectiveness against laboratory-confirmed influenza in hospitalised adults aged 60 years or older, Valencia Region, Spain, 2017/18 influenza season. Eurosurveillance 2019, 24, 1 .
AMA StyleAinara Mira-Iglesias, F Xavier López-Labrador, Víctor Baselga-Moreno, Miguel Tortajada-Girbés, Juan Mollar-Maseres, Mario Carballido-Fernández, Germán Schwarz-Chavarri, Joan Puig-Barberà, Javier Díez-Domingo, on behalf of the Valencia Hospital Network for the Study of Influenza and Respiratory Viruses Disease. Influenza vaccine effectiveness against laboratory-confirmed influenza in hospitalised adults aged 60 years or older, Valencia Region, Spain, 2017/18 influenza season. Eurosurveillance. 2019; 24 (31):1.
Chicago/Turabian StyleAinara Mira-Iglesias; F Xavier López-Labrador; Víctor Baselga-Moreno; Miguel Tortajada-Girbés; Juan Mollar-Maseres; Mario Carballido-Fernández; Germán Schwarz-Chavarri; Joan Puig-Barberà; Javier Díez-Domingo; on behalf of the Valencia Hospital Network for the Study of Influenza and Respiratory Viruses Disease. 2019. "Influenza vaccine effectiveness against laboratory-confirmed influenza in hospitalised adults aged 60 years or older, Valencia Region, Spain, 2017/18 influenza season." Eurosurveillance 24, no. 31: 1.
The Global Influenza Hospital Surveillance Network is an international platform whose primary objective is to study severe cases of influenza requiring hospitalization. During the 2015–2016 influenza season, 11 sites in the Global Influenza Hospital Surveillance Network in nine countries (Russian Federation, Czech Republic, Turkey, France, China, Spain, Mexico, India, and Brazil) participated in a prospective, active-surveillance, hospital-based epidemiological study. Influenza infection was confirmed by reverse transcription-polymerase chain reaction. Influenza vaccine effectiveness (IVE) against laboratory-confirmed influenza was estimated using a test-negative approach. 9882 patients with laboratory results were included of which 2415 (24.4%) were positive for influenza, including 1415 (14.3%) for A(H1N1)pdm09, 235 (2.4%) for A(H3N2), 180 (1.8%) for A not subtyped, 45 (0.5%) for B/Yamagata-lineage, 532 (5.4%) for B/Victoria-lineage, and 33 (0.3%) for B not subtyped. Of included admissions, 39% were < 5 years of age and 67% had no underlying conditions. The odds of being admitted with influenza were higher among pregnant than non-pregnant women (odds ratio, 2.82 [95% confidence interval (CI), 1.90 to 4.19]). Adjusted IVE against influenza-related hospitalization was 16.3% (95% CI, 0.4 to 29.7). Among patients targeted for influenza vaccination, adjusted IVE against hospital admission with influenza was 16.2% (95% CI, − 3.6 to 32.2) overall, 23.0% (95% CI, − 3.3 to 42.6) against A(H1N1)pdm09, and − 25.6% (95% CI, − 86.3 to 15.4) against B/Victoria lineage. The 2015–2016 influenza season was dominated by A(H1N1)pdm09 and B/Victoria-lineage. Hospitalization with influenza often occurred in healthy and young individuals, and pregnant women were at increased risk of influenza-related hospitalization. Influenza vaccines provided low to moderate protection against hospitalization with influenza and no protection against the predominant circulating B lineage, highlighting the need for more effective and broader influenza vaccines.
Joan Puig-Barberà; on behalf of the Global Influenza Hospital Surveillance Network; Ainara Mira-Iglesias; Elena Burtseva; Benjamin J. Cowling; Unal Serhat; Guillermo Miguel Ruiz-Palacios; Odile Launay; Jan Kyncl; Parvaiz Koul; Marilda M. Siqueira; Anna Sominina. Influenza epidemiology and influenza vaccine effectiveness during the 2015–2016 season: results from the Global Influenza Hospital Surveillance Network. BMC Infectious Diseases 2019, 19, 415 .
AMA StyleJoan Puig-Barberà, on behalf of the Global Influenza Hospital Surveillance Network, Ainara Mira-Iglesias, Elena Burtseva, Benjamin J. Cowling, Unal Serhat, Guillermo Miguel Ruiz-Palacios, Odile Launay, Jan Kyncl, Parvaiz Koul, Marilda M. Siqueira, Anna Sominina. Influenza epidemiology and influenza vaccine effectiveness during the 2015–2016 season: results from the Global Influenza Hospital Surveillance Network. BMC Infectious Diseases. 2019; 19 (1):415.
Chicago/Turabian StyleJoan Puig-Barberà; on behalf of the Global Influenza Hospital Surveillance Network; Ainara Mira-Iglesias; Elena Burtseva; Benjamin J. Cowling; Unal Serhat; Guillermo Miguel Ruiz-Palacios; Odile Launay; Jan Kyncl; Parvaiz Koul; Marilda M. Siqueira; Anna Sominina. 2019. "Influenza epidemiology and influenza vaccine effectiveness during the 2015–2016 season: results from the Global Influenza Hospital Surveillance Network." BMC Infectious Diseases 19, no. 1: 415.
The Global Influenza Hospital Surveillance Network (GIHSN) aims to determine the burden of severe influenza disease and Influenza Vaccine Effectiveness (IVE). This is a prospective, active surveillance and hospital-based epidemiological study to collect epidemiological data in the GIHSN. In the 2016-2017 influenza season, 15 sites in 14 countries participated in the GIHSN, although the analyses could not be performed in 2 sites. A common core protocol was used in order to make results comparable. Here we present the results of the GIHSN 2016-2017 influenza season. A RT-PCR test was performed to all patients that accomplished the requirements detailed on a common core protocol. Patients admitted were included in the study after signing the informed consent, if they were residents, not institutionalised, not discharged in the previous 30 days from other hospitalisation with symptoms onset within the 7 days prior to admission. Patients 5 years old or more must also complied the Influenza-Like Illness definition. A test negative-design was implemented to perform IVE analysis. IVE was estimated using a logistic regression model, with the formula IVE = (1-aOR) × 100, where aOR is the adjusted Odds Ratio comparing cases and controls. Among 21,967 screened patients, 10,140 (46.16%) were included, as they accomplished the inclusion criteria, and tested, and therefore 11,827 (53.84%) patients were excluded. Around 60% of all patients included with laboratory results were recruited at 3 sites. The predominant strain was A(H3N2), detected in 63.6% of the cases (1840 patients), followed by B/Victoria, in 21.3% of the cases (618 patients). There were 2895 influenza positive patients (28.6% of the included patients). A(H1N1)pdm09 strain was mainly found in Mexico. IVE could only be performed in 6 sites separately. Overall IVE was 27.24 (95% CI 15.62-37.27. Vaccination seemed to confer better protection against influenza B and in people 2-4 years, or 85 years old or older. The aOR for hospitalized and testing positive for influenza was 3.02 (95% CI 1.59-5.76) comparing pregnant with non-pregnant women. Vaccination prevented around 1 in 4 hospitalisations with influenza. Sparse numbers didn't allow estimating IVE in all sites separately. Pregnancy was found a risk factor for influenza, having 3 times more risk of being admitted with influenza for pregnant women.
Víctor Baselga-Moreno; for the Global Influenza Hospital Surveillance Network (GIHSN); Svetlana Trushakova; Shelly McNeil; Anna Sominina; Marta C. Nunes; Anca Draganescu; Serhat Unal; Parvaiz Koul; Jan Kyncl; Tao Zhang; Ainagul Kuatbayeva; Afif Ben-Salah; Elena Burtseva; Joan Puig-Barberà; Javier Díez-Domingo; B. Escribano-López. Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN). BMC Public Health 2019, 19, 487 .
AMA StyleVíctor Baselga-Moreno, for the Global Influenza Hospital Surveillance Network (GIHSN), Svetlana Trushakova, Shelly McNeil, Anna Sominina, Marta C. Nunes, Anca Draganescu, Serhat Unal, Parvaiz Koul, Jan Kyncl, Tao Zhang, Ainagul Kuatbayeva, Afif Ben-Salah, Elena Burtseva, Joan Puig-Barberà, Javier Díez-Domingo, B. Escribano-López. Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN). BMC Public Health. 2019; 19 (1):487.
Chicago/Turabian StyleVíctor Baselga-Moreno; for the Global Influenza Hospital Surveillance Network (GIHSN); Svetlana Trushakova; Shelly McNeil; Anna Sominina; Marta C. Nunes; Anca Draganescu; Serhat Unal; Parvaiz Koul; Jan Kyncl; Tao Zhang; Ainagul Kuatbayeva; Afif Ben-Salah; Elena Burtseva; Joan Puig-Barberà; Javier Díez-Domingo; B. Escribano-López. 2019. "Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN)." BMC Public Health 19, no. 1: 487.
To better understand the impact of seasonal influenza in pregnant women we analyzed data collected during four seasons at a hospital for acute respiratory infection that specializes in treating pregnant women. This was a single-center active surveillance study of women 15–44 years of age hospitalized for acute respiratory diseases between 2012/2013 and 2015/2016 in Moscow, Russian Federation. Women had to have been hospitalized within 7 days of the onset of symptoms. Swabs were taken within 48 h of admission, and influenza was detected by reverse transcription-polymerase chain reaction. During the four seasons, of the 1992 hospitalized women 1748 were pregnant. Laboratory-confirmed influenza was detected more frequently in pregnant women (825/1748; 47.2%) than non-pregnant women (58/244; 23.8%) (OR for influenza = 2.87 [95% CI, 2.10–3.92]; p < 0.001). This pattern was homogenous across seasons (p = 0.112 by test of homogeneity of equal odds). Influenza A(H1N1)pdm09 was the dominant strain in 2012/2013, A(H3N2) in 2013/2014, B/Yamagata lineage and A(H3N2) in 2014/2015, and A(H1N1)pdm09 in 2015/2016. Influenza-positive pregnant admissions went to the hospital sooner than influenza-negative pregnant admissions (p < 0.001). The risk of influenza increased by 2% with each year of age and was higher in women with underlying conditions (OR = 1.52 [95% CI, 1.16 to 1.99]). Pregnant women positive for influenza were homogeneously distributed by trimester (p = 0.37 for homogeneity; p = 0.49 for trend). Frequencies of stillbirth, delivery, preterm delivery, and caesarean delivery did not significantly differ between influenza-positive and influenza-negative hospitalized pregnant women or between subtypes/lineages. Pregnant women are at increased risk for hospitalization due to influenza irrespective of season, circulating viruses, or trimester.
Svetlana Trushakova; Lidiya Kisteneva; Beatriz Guglieri-López; Evgenia Mukasheva; Irina Kruzhkova; Ainara Mira-Iglesias; Kirill Krasnoslobodtsev; Ekaterina Morozova; Ludmila Kolobukhina; Joan Puig-Barberà; Elena Burtseva. Epidemiology of influenza in pregnant women hospitalized with respiratory illness in Moscow, 2012/2013–2015/2016: a hospital-based active surveillance study. BMC Pregnancy and Childbirth 2019, 19, 1 -14.
AMA StyleSvetlana Trushakova, Lidiya Kisteneva, Beatriz Guglieri-López, Evgenia Mukasheva, Irina Kruzhkova, Ainara Mira-Iglesias, Kirill Krasnoslobodtsev, Ekaterina Morozova, Ludmila Kolobukhina, Joan Puig-Barberà, Elena Burtseva. Epidemiology of influenza in pregnant women hospitalized with respiratory illness in Moscow, 2012/2013–2015/2016: a hospital-based active surveillance study. BMC Pregnancy and Childbirth. 2019; 19 (1):1-14.
Chicago/Turabian StyleSvetlana Trushakova; Lidiya Kisteneva; Beatriz Guglieri-López; Evgenia Mukasheva; Irina Kruzhkova; Ainara Mira-Iglesias; Kirill Krasnoslobodtsev; Ekaterina Morozova; Ludmila Kolobukhina; Joan Puig-Barberà; Elena Burtseva. 2019. "Epidemiology of influenza in pregnant women hospitalized with respiratory illness in Moscow, 2012/2013–2015/2016: a hospital-based active surveillance study." BMC Pregnancy and Childbirth 19, no. 1: 1-14.
Introduction Seasonal influenza vaccination is widely recommended for people with risk factors, especially for people who are elderly. However, influenza vaccine effectiveness (IVE) varies year after year because of the variable antigenic composition of the circulating viruses and the vaccine composition. Methods: We summarise the results of IVE and the impact of previous vaccination among subjects 60 years of age and over in a multicentre prospective study in the Valencia Hospital Surveillance Network for the Study of Influenza and Respiratory Viruses Disease (VAHNSI) in Spain. We applied the test-negative design taking laboratory-confirmed influenza as outcome and vaccination status as exposure. Information about potential confounders was obtained from clinical registries or directly from patients. Results: Adjusted IVE was 19% (95% confidence interval (CI): −15 to 43). For patients vaccinated in the current season but not in the two previous seasons, effectiveness was 49% (95% CI: −20 to 78) and for patients vaccinated in the current and any of two previous seasons, effectiveness was 29% (95% CI: −3 to 52). For those patients not vaccinated in the current season but vaccinated in any of the two previous seasons, effectiveness was 53% (95% CI: 8 to 76). Conclusions: Our data show a low vaccine effectiveness for the 2016/17 influenza season.
Ainara Mira-Iglesias; F Xavier López-Labrador; Beatriz Guglieri-López; Miguel Tortajada-Girbés; Víctor Baselga-Moreno; Laura Cano; Juan Mollar-Maseres; Mario Carballido-Fernández; Germán Schwarz-Chavarri; Javier Díez-Domingo; Joan Puig-Barberà; Valencia Hospital Network for the Study of Influenza and Respiratory Viruses Disease. Influenza vaccine effectiveness in preventing hospitalisation of individuals 60 years of age and over with laboratory-confirmed influenza, Valencia Region, Spain, influenza season 2016/17. Eurosurveillance 2018, 23, 17-00318 .
AMA StyleAinara Mira-Iglesias, F Xavier López-Labrador, Beatriz Guglieri-López, Miguel Tortajada-Girbés, Víctor Baselga-Moreno, Laura Cano, Juan Mollar-Maseres, Mario Carballido-Fernández, Germán Schwarz-Chavarri, Javier Díez-Domingo, Joan Puig-Barberà, Valencia Hospital Network for the Study of Influenza and Respiratory Viruses Disease. Influenza vaccine effectiveness in preventing hospitalisation of individuals 60 years of age and over with laboratory-confirmed influenza, Valencia Region, Spain, influenza season 2016/17. Eurosurveillance. 2018; 23 (8):17-00318.
Chicago/Turabian StyleAinara Mira-Iglesias; F Xavier López-Labrador; Beatriz Guglieri-López; Miguel Tortajada-Girbés; Víctor Baselga-Moreno; Laura Cano; Juan Mollar-Maseres; Mario Carballido-Fernández; Germán Schwarz-Chavarri; Javier Díez-Domingo; Joan Puig-Barberà; Valencia Hospital Network for the Study of Influenza and Respiratory Viruses Disease. 2018. "Influenza vaccine effectiveness in preventing hospitalisation of individuals 60 years of age and over with laboratory-confirmed influenza, Valencia Region, Spain, influenza season 2016/17." Eurosurveillance 23, no. 8: 17-00318.
BackgroundInfluenza-like illness occurs annually worldwide, with peak timing and severity varying seasonally, resulting in significant annual mortality.ObjectivesThere were three objectives: (1) to describe the epidemiological and clinical features of hospitalised patients with severe acute respiratory infection caused by influenza and other respiratory viruses (ORVs); (2) to report the influenza seasonality in the region and (3) to correlate findings of influenza circulation and immunisation time in Brazil.Patients/methodsThis study took place in three Brazilian hospitals located in cities with different climatic conditions (Curitiba (south), Rio de Janeiro (south-east) and Fortaleza (north-east)). Patients presenting with an acute process with indication for admission consisting of a predefined set of conditions potentially associated with recent influenza infection were enrolled.ResultsWe screened 1666 patients, with 595 meeting the inclusion criteria. Influenza viruses and ORVs were detected in 6.5% and 59% of patients, respectively. Influenza-positive cases fell into the severe spectrum as compared with those with ORVs (30% vs 11%), but without any difference in mortality rates. Epidemiological results revealed variations in the peak time of influenza infections between north-east (Fortaleza) and south (Curitiba) Brazil, basically following the rain period of each region. In north-east Brazil, viral circulation was prevalent in the first 4 months of the year, indicating that the vaccination campaign occurred in a postseasonal period, possibly explaining the low effectiveness.ConclusionsThe active-surveillance model is a valuable tool for investigating respiratory virus impact on hospitalised patients, with influenza-infection monitoring enabling implementation of adequate preventive measures.
Sonia M Raboni; Fernanda E A Moura; Braulia C Caetano; Valéria M Avanzi; Luciane A Pereira; Meri B Nogueira; Luine R Vidal; Isabel C F Tavares; Florence Pradel; Valentina S Picot; Joan Puig-Barberà; Marilda M Siqueira. Global Influenza Hospital-based Surveillance Network (GIHSN): results of surveillance of influenza and other respiratory viruses in hospitalised patients in Brazil, 2015. BMJ Open 2018, 8, e017603 .
AMA StyleSonia M Raboni, Fernanda E A Moura, Braulia C Caetano, Valéria M Avanzi, Luciane A Pereira, Meri B Nogueira, Luine R Vidal, Isabel C F Tavares, Florence Pradel, Valentina S Picot, Joan Puig-Barberà, Marilda M Siqueira. Global Influenza Hospital-based Surveillance Network (GIHSN): results of surveillance of influenza and other respiratory viruses in hospitalised patients in Brazil, 2015. BMJ Open. 2018; 8 (2):e017603.
Chicago/Turabian StyleSonia M Raboni; Fernanda E A Moura; Braulia C Caetano; Valéria M Avanzi; Luciane A Pereira; Meri B Nogueira; Luine R Vidal; Isabel C F Tavares; Florence Pradel; Valentina S Picot; Joan Puig-Barberà; Marilda M Siqueira. 2018. "Global Influenza Hospital-based Surveillance Network (GIHSN): results of surveillance of influenza and other respiratory viruses in hospitalised patients in Brazil, 2015." BMJ Open 8, no. 2: e017603.
The 2015/2016 influenza season was characterized in Europe by the circulation of A(H1N1)pdm09 clade 6B.1 and B/Victoria-lineage influenza viruses. The components of the vaccines used in the current and past two seasons in the Valencia region were similar but not well matched to the 2015/2016 dominant influenza-circulating strains. We estimate influenza vaccine effectiveness (IVE) and interference of previous vaccination in preventing admission with A(H1N1)pdm09 or B/Victoria-lineage in this particular season.
Joan Puig-Barberà; Beatriz Guglieri-López; Miguel Tortajada-Girbés; F. Xavier López-Labrador; Mario Carballido-Fernández; Joan Mollar-Maseres; Germán Schwarz-Chavarri; Víctor Baselga-Moreno; Ainara Mira-Iglesias; Javier Díez-Domingo. Low influenza vaccine effectiveness and the effect of previous vaccination in preventing admission with A(H1N1)pdm09 or B/Victoria-Lineage in patients 60 years old or older during the 2015/2016 influenza season. Vaccine 2017, 35, 7331 -7338.
AMA StyleJoan Puig-Barberà, Beatriz Guglieri-López, Miguel Tortajada-Girbés, F. Xavier López-Labrador, Mario Carballido-Fernández, Joan Mollar-Maseres, Germán Schwarz-Chavarri, Víctor Baselga-Moreno, Ainara Mira-Iglesias, Javier Díez-Domingo. Low influenza vaccine effectiveness and the effect of previous vaccination in preventing admission with A(H1N1)pdm09 or B/Victoria-Lineage in patients 60 years old or older during the 2015/2016 influenza season. Vaccine. 2017; 35 (52):7331-7338.
Chicago/Turabian StyleJoan Puig-Barberà; Beatriz Guglieri-López; Miguel Tortajada-Girbés; F. Xavier López-Labrador; Mario Carballido-Fernández; Joan Mollar-Maseres; Germán Schwarz-Chavarri; Víctor Baselga-Moreno; Ainara Mira-Iglesias; Javier Díez-Domingo. 2017. "Low influenza vaccine effectiveness and the effect of previous vaccination in preventing admission with A(H1N1)pdm09 or B/Victoria-Lineage in patients 60 years old or older during the 2015/2016 influenza season." Vaccine 35, no. 52: 7331-7338.
Concerns have been raised about intraseasonal waning of the protection conferred by influenza vaccination.During four influenza seasons, we consecutively recruited individuals aged 18years or older who had received seasonal influenza vaccine and were subsequently admitted to the hospital for influenza infection, asassessed by reverse transcription polymerase chain reaction. We estimated the adjusted odds ratio (aOR) of influenza infection by date of vaccination, defined by tertiles, as early, intermediate or late vaccination. We used a test-negative approach with early vaccination as reference to estimate the aOR of hospital admission with influenza among late vaccinees. We conducted sensitivity analyses by means of conditional logistic regression, Cox proportional hazards regression, and using days between vaccination and hospital admission rather than vaccination date.Among 3615 admitted vaccinees, 822 (23%) were positive for influenza. We observed a lower risk of influenza among late vaccinees during the 2011/2012 and 2014/2015A(H3N2)-dominant seasons: aOR=0.68 (95% CI: 0.47-1.00) and 0.69 (95% CI: 0.50-0.95). We found no differences in the risk of admission with influenza among late versus early vaccinees in the 2012/2013A(H1N1)pdm09-dominant or 2013/2014B/Yamagata lineage-dominant seasons: aOR=1.18 (95% CI: 0.58-2.41) and 0.98 (95% CI: 0.56-1.72). When we restricted our analysis to individuals aged 65years or older, we found a statistically significant lower risk of admission with influenza among late vaccinees during the 2011/2012 and 2014/2015A(H3N2)-dominant seasons: aOR=0.61 (95% CI: 0.41-0.91) and 0.69 (95% CI: 0.49-0.96). We observed 39% (95% CI: 9-59%) and 31% (95% CI: 5-50%) waning of vaccine effectiveness among participants aged 65years or older during the two A(H3N2)-dominant seasons. Similar results were obtained in the sensitivity analyses.Waning of vaccine protection was observed among individuals aged 65years old or over in two A(H3N2)-dominant influenza seasons.
J. Puig-Barberà; A. Mira-Iglesias; M. Tortajada-Girbés; F.X. López-Labrador; J. Librero-López; J. Díez-Domingo; M. Carballido-Fernández; C. Carratalá-Munuera; P Correcher-Medina; V. Gil-Guillén; R. Limón-Ramírez; J. Mollar-Maseres; M.C. Otero-Reigada; H. Schwarz. Waning protection of influenza vaccination during four influenza seasons, 2011/2012 to 2014/2015. Vaccine 2017, 35, 5799 -5807.
AMA StyleJ. Puig-Barberà, A. Mira-Iglesias, M. Tortajada-Girbés, F.X. López-Labrador, J. Librero-López, J. Díez-Domingo, M. Carballido-Fernández, C. Carratalá-Munuera, P Correcher-Medina, V. Gil-Guillén, R. Limón-Ramírez, J. Mollar-Maseres, M.C. Otero-Reigada, H. Schwarz. Waning protection of influenza vaccination during four influenza seasons, 2011/2012 to 2014/2015. Vaccine. 2017; 35 (43):5799-5807.
Chicago/Turabian StyleJ. Puig-Barberà; A. Mira-Iglesias; M. Tortajada-Girbés; F.X. López-Labrador; J. Librero-López; J. Díez-Domingo; M. Carballido-Fernández; C. Carratalá-Munuera; P Correcher-Medina; V. Gil-Guillén; R. Limón-Ramírez; J. Mollar-Maseres; M.C. Otero-Reigada; H. Schwarz. 2017. "Waning protection of influenza vaccination during four influenza seasons, 2011/2012 to 2014/2015." Vaccine 35, no. 43: 5799-5807.
In Europe, annual influenza vaccination is recommended to elderly. From 2011 to 2014 and in 2015-16, we conducted a multicentre test negative case control study in hospitals of 11 European countries to measure influenza vaccine effectiveness (IVE) against laboratory confirmed hospitalised influenza among people aged ≥65years. We pooled four seasons data to measure IVE by past exposures to influenza vaccination. We swabbed patients admitted for clinical conditions related to influenza with onset of severe acute respiratory infection ≤7days before admission. Cases were patients RT-PCR positive for influenza virus and controls those negative for any influenza virus. We documented seasonal vaccination status for the current season and the two previous seasons. We recruited 5295 patients over the four seasons, including 465A(H1N1)pdm09, 642A(H3N2), 278 B case-patients and 3910 controls. Among patients unvaccinated in both previous two seasons, current seasonal IVE (pooled across seasons) was 30% (95%CI: -35 to 64), 8% (95%CI: -94 to 56) and 33% (95%CI: -43 to 68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively. Among patients vaccinated in both previous seasons, current seasonal IVE (pooled across seasons) was -1% (95%CI: -80 to 43), 37% (95%CI: 7-57) and 43% (95%CI: 1-68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively. Our results suggest that, regardless of patients' recent vaccination history, current seasonal vaccine conferred some protection to vaccinated patients against hospitalisation with influenza A(H3N2) and B. Vaccination of patients already vaccinated in both the past two seasons did not seem to be effective against A(H1N1)pdm09. To better understand the effect of repeated vaccination, engaging in large cohort studies documenting exposures to vaccine and natural infection is needed.The Lithuanian I-MOVE+ study sites were supported by a grant from the Research Council of Lithuania (SEN-03/2015). The IMOVE+ project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446. GlaxoSmithKline, Sanofi Pasteur and Sanofi Pasteur MSD financially supported the InNHOVE network. They had no role in study design, data collection, pooled analysis, and publication. We are grateful to all patients, medical staff, study nurses and epidemiologists from the twelve study sites who actively participated in the study.info:eu-repo/semantics/publishedVersio
Marc Rondy; Odile Launay; Jesus Castilla; Simona Costanzo; Joan Puig-Barberà; Giedre Gefenaite; Amparo Larrauri; Caterina Rizzo; Daniela Pitigoi; Ritva K. Syrjänen; Ausenda Machado; Sanja Kurečić Filipović; Judit Krisztina Horváth; Iwona Paradowska-Stankiewicz; Sierk Marbus; Alain Moren. Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza. Vaccine 2017, 35, 4298 -4306.
AMA StyleMarc Rondy, Odile Launay, Jesus Castilla, Simona Costanzo, Joan Puig-Barberà, Giedre Gefenaite, Amparo Larrauri, Caterina Rizzo, Daniela Pitigoi, Ritva K. Syrjänen, Ausenda Machado, Sanja Kurečić Filipović, Judit Krisztina Horváth, Iwona Paradowska-Stankiewicz, Sierk Marbus, Alain Moren. Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza. Vaccine. 2017; 35 (34):4298-4306.
Chicago/Turabian StyleMarc Rondy; Odile Launay; Jesus Castilla; Simona Costanzo; Joan Puig-Barberà; Giedre Gefenaite; Amparo Larrauri; Caterina Rizzo; Daniela Pitigoi; Ritva K. Syrjänen; Ausenda Machado; Sanja Kurečić Filipović; Judit Krisztina Horváth; Iwona Paradowska-Stankiewicz; Sierk Marbus; Alain Moren. 2017. "Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza." Vaccine 35, no. 34: 4298-4306.
Only one in three subjects who were vaccinated with MCC vaccine was seroprotected after 8-12years. These findings emphasize that seroprevalence studies are essential to identify susceptible cohorts and to inform vaccine policy.
Lina Pérez-Breva; Raquel Abad-Torreblanca; Miguel Ángel Martínez-Beneito; Joan Puig-Barberà; Sara Alemán-Sánchez; Nuria Morant-Talamante; Macrina Sastre-Cantón; Julio A. Vázquez-Moreno; Javier Díez-Domingo. Seroprevalence of antibodies against serogroup C meningococci in the region of Valencia, Spain: Impact of meningococcal C conjugate vaccination. Vaccine 2017, 35, 2949 -2954.
AMA StyleLina Pérez-Breva, Raquel Abad-Torreblanca, Miguel Ángel Martínez-Beneito, Joan Puig-Barberà, Sara Alemán-Sánchez, Nuria Morant-Talamante, Macrina Sastre-Cantón, Julio A. Vázquez-Moreno, Javier Díez-Domingo. Seroprevalence of antibodies against serogroup C meningococci in the region of Valencia, Spain: Impact of meningococcal C conjugate vaccination. Vaccine. 2017; 35 (22):2949-2954.
Chicago/Turabian StyleLina Pérez-Breva; Raquel Abad-Torreblanca; Miguel Ángel Martínez-Beneito; Joan Puig-Barberà; Sara Alemán-Sánchez; Nuria Morant-Talamante; Macrina Sastre-Cantón; Julio A. Vázquez-Moreno; Javier Díez-Domingo. 2017. "Seroprevalence of antibodies against serogroup C meningococci in the region of Valencia, Spain: Impact of meningococcal C conjugate vaccination." Vaccine 35, no. 22: 2949-2954.
Vaccination is recommended to prevent influenza virus infection and associated complications. This study aimed to estimate the influenza vaccine effectiveness (VE) against hospitalization in the 2015/16 season in Beijing. Patients who were hospitalized in the 5 study hospitals between 1 Oct 2015 and 15 May 2016 were recruited. Influenza vaccination status was obtained for PCR-confirmed influenza patients and the selected controls who tested negative for the virus. Conditional logistic regression was used to estimate the influenza VE matching by calendar week, and adjusting for age, study sites, underlying medical conditions, smoking status, and hospital admissions over the past 12 months. The overall VE was −37.9% (95% CI: −103.3, 6.5) against laboratory-confirmed influenza-associated hospitalization. The 2015–16 seasonal vaccine was had −61.9% (95% CI: −211.9, 15.9), −5.4% (95% CI: −108.1, 46.6) and −45.2% (95% CI: −152.6, 16.5) effectiveness to prevent infection from A(H1N1)pdm09, A(H3N2) and influenza B, respectively. Influenza vaccination did not show effective protection against hospitalization with influenza in 2015/16 season in Beijing.
Yi Zhang; Peng Wu; Luzhao Feng; Peng Yang; Yang Pan; Shuo Feng; Ying Qin; Jiandong Zheng; Joan Puig-Barberà; David Muscatello; Raina MacIntyre; Benjamin J. Cowling; Hongjie Yu; Quanyi Wang. Influenza vaccine effectiveness against influenza-associated hospitalization in 2015/16 season, Beijing, China. Vaccine 2017, 35, 3129 -3134.
AMA StyleYi Zhang, Peng Wu, Luzhao Feng, Peng Yang, Yang Pan, Shuo Feng, Ying Qin, Jiandong Zheng, Joan Puig-Barberà, David Muscatello, Raina MacIntyre, Benjamin J. Cowling, Hongjie Yu, Quanyi Wang. Influenza vaccine effectiveness against influenza-associated hospitalization in 2015/16 season, Beijing, China. Vaccine. 2017; 35 (23):3129-3134.
Chicago/Turabian StyleYi Zhang; Peng Wu; Luzhao Feng; Peng Yang; Yang Pan; Shuo Feng; Ying Qin; Jiandong Zheng; Joan Puig-Barberà; David Muscatello; Raina MacIntyre; Benjamin J. Cowling; Hongjie Yu; Quanyi Wang. 2017. "Influenza vaccine effectiveness against influenza-associated hospitalization in 2015/16 season, Beijing, China." Vaccine 35, no. 23: 3129-3134.
In the elderly, traditional influenza inactivated vaccines are often only modestly immunogenic, owing to immunosenescence. Given that adjuvantation is a means of enhancing the immune response, the trivalent inactivated vaccine adjuvanted with MF59 (MF59-TIV) was specifically designed to overcome this problem. Considering that, for ethical reasons, the absolute effectiveness of an influenza vaccine in the elderly cannot be demonstrated in placebo-controlled studies, the present study aimed to assess the effectiveness of MF59-TIV in preventing influenza-related outcomes in the elderly. We conducted a systematic review of observational studies aimed at evaluating the effectiveness of MF59-TIV against influenza-related outcomes. Results of single studies were pooled whenever possible. Of the 1993 papers screened, 11 (6 case-control, 3 cohort and 2 prospective case-control) studies were identified. Hospitalization due to pneumonia/influenza and laboratory-confirmed influenza were reported in more than one study, while other outcomes (influenza-like illness, cardio- and cerebrovascular accidents) were investigated only by one study each. Pooled analysis of four case-control studies showed an adjusted MF59-TIV effectiveness of 51% (95% CI: 39–61%) against hospitalizations for pneumonia/influenza among community-dwelling seniors. Pooled results of the adjusted vaccine effectiveness against laboratory-confirmed influenza were also high (60.1%), although the 95% CI passed through zero (−1.3 to 84.3%). Other single community-based studies showed very high effectiveness of MF59-TIV in preventing hospitalizations for acute coronary [87% (95% CI: 35–97%)] and cerebrovascular [93% (95% CI: 52–99%)] events. MF59-TIV proved highly effective [94% (95% CI: 47–100%] in reducing influenza-like illness among institutionalized elderly. Furthermore, MF59-TIV displayed greater efficacy than non-adjuvanted vaccines in preventing hospitalizations due to pneumonia/influenza [adjusted risk ratio 0.75 (95% CI: 0.57–0.98)] and laboratory-confirmed influenza [adjusted odds ratio 0.37 (0.14–0.96)]. Our results suggest that MF59-TIV is effective in reducing several influenza-related outcomes among the elderly, especially hospitalizations due to influenza-related complications.
Alexander Domnich; Lucia Arata; Daniela Amicizia; Joan Puig-Barberà; Roberto Gasparini; Donatella Panatto. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis. Vaccine 2016, 35, 513 -520.
AMA StyleAlexander Domnich, Lucia Arata, Daniela Amicizia, Joan Puig-Barberà, Roberto Gasparini, Donatella Panatto. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis. Vaccine. 2016; 35 (4):513-520.
Chicago/Turabian StyleAlexander Domnich; Lucia Arata; Daniela Amicizia; Joan Puig-Barberà; Roberto Gasparini; Donatella Panatto. 2016. "Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis." Vaccine 35, no. 4: 513-520.
C. Muñoz-Quiles; M. López-Lacort; R. Doménech-Clar; Joan Puig-Barberà; Javier Diez-Domingo. Infecciones por virus respiratorio sincitial en adultos diagnosticados en la Comunidad Valenciana. Revista Clínica Española 2016, 216, 508 -510.
AMA StyleC. Muñoz-Quiles, M. López-Lacort, R. Doménech-Clar, Joan Puig-Barberà, Javier Diez-Domingo. Infecciones por virus respiratorio sincitial en adultos diagnosticados en la Comunidad Valenciana. Revista Clínica Española. 2016; 216 (9):508-510.
Chicago/Turabian StyleC. Muñoz-Quiles; M. López-Lacort; R. Doménech-Clar; Joan Puig-Barberà; Javier Diez-Domingo. 2016. "Infecciones por virus respiratorio sincitial en adultos diagnosticados en la Comunidad Valenciana." Revista Clínica Española 216, no. 9: 508-510.
F. Xavier López-Labrador; Angels Natividad-Sancho; Maria Pisareva; Andrey Komissarov; Karina Salvatierra; Artem Fadeev; Andrés Moya; Mikhail Grudinin; Javier Díez-Domingo; Olga Afanasieva; Nadezhda Konovalova; Anna Sominina; Joan Puig-Barberà. Genetic characterization of influenza viruses from influenza-related hospital admissions in the St. Petersburg and Valencia sites of the Global Influenza Hospital Surveillance Network during the 2013/14 influenza season. Journal of Clinical Virology 2016, 84, 32 -38.
AMA StyleF. Xavier López-Labrador, Angels Natividad-Sancho, Maria Pisareva, Andrey Komissarov, Karina Salvatierra, Artem Fadeev, Andrés Moya, Mikhail Grudinin, Javier Díez-Domingo, Olga Afanasieva, Nadezhda Konovalova, Anna Sominina, Joan Puig-Barberà. Genetic characterization of influenza viruses from influenza-related hospital admissions in the St. Petersburg and Valencia sites of the Global Influenza Hospital Surveillance Network during the 2013/14 influenza season. Journal of Clinical Virology. 2016; 84 ():32-38.
Chicago/Turabian StyleF. Xavier López-Labrador; Angels Natividad-Sancho; Maria Pisareva; Andrey Komissarov; Karina Salvatierra; Artem Fadeev; Andrés Moya; Mikhail Grudinin; Javier Díez-Domingo; Olga Afanasieva; Nadezhda Konovalova; Anna Sominina; Joan Puig-Barberà. 2016. "Genetic characterization of influenza viruses from influenza-related hospital admissions in the St. Petersburg and Valencia sites of the Global Influenza Hospital Surveillance Network during the 2013/14 influenza season." Journal of Clinical Virology 84, no. : 32-38.